Clinical Trial Update: Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for recurrent glioblastoma evaluating a TIM-3–targeting antibody in combination with PD-1 blockade and stereotactic radiosurgery; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Anti-PD-1 antibody
• Anti-TIM-3 antibody (TIM-3 antagonist)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Glioblastoma Multiforme | Phase 1 | Status: ACTIVE_NOT_RECRUITING